LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Search

Simulations Plus Inc

Cerrado

SectorSanidad

15.22 -0.52

Resumen

Variación precio

24h

Actual

Mínimo

14.98

Máximo

15.68

Métricas clave

By Trading Economics

Ingresos

3.9M

4.5M

Ventas

5.9M

24M

BPA

0.35

Rentabilidad por dividendo

0.48

Margen de beneficios

18.669

Empleados

212

EBITDA

4.9M

7.2M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+4.1% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.48%

2.39%

Próximas Ganancias

13 jul 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

27M

278M

Apertura anterior

15.74

Cierre anterior

15.22

Noticias sobre sentimiento de mercado

By Acuity

19%

81%

26 / 344 Clasificación en Healthcare

Simulations Plus Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

26 may 2026, 16:52 UTC

Noticias de Eventos Importantes

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 may 2026, 23:57 UTC

Ganancias

Sociedad Quimica 1Q Rev $1.76B >SQM

26 may 2026, 23:57 UTC

Ganancias

Sociedad Quimica 1Q EPS $1.28 >SQM

26 may 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 may 2026, 21:54 UTC

Ganancias

Webco Industries 3Q EPS $11.61 >WEBC

26 may 2026, 21:54 UTC

Ganancias

Webco Industries 3Q Sales $179.6M >WEBC

26 may 2026, 21:48 UTC

Charlas de Mercado

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 may 2026, 21:00 UTC

Charlas de Mercado

ESG Roundup: Market Talk

26 may 2026, 20:58 UTC

Adquisiciones, fusiones, absorciones

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 may 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 may 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

26 may 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

26 may 2026, 19:22 UTC

Charlas de Mercado

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 may 2026, 19:17 UTC

Charlas de Mercado

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 may 2026, 18:56 UTC

Charlas de Mercado

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 may 2026, 18:03 UTC

Charlas de Mercado

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 may 2026, 17:42 UTC

Charlas de Mercado

Grains Await Fresh Trading Catalyst -- Market Talk

26 may 2026, 17:33 UTC

Charlas de Mercado

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 may 2026, 17:21 UTC

Charlas de Mercado

Canada Faces a Labor Market Squeeze -- Market Talk

26 may 2026, 16:52 UTC

Charlas de Mercado

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 may 2026, 16:43 UTC

Charlas de Mercado

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 may 2026, 16:24 UTC

Charlas de Mercado

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 may 2026, 16:21 UTC

Charlas de Mercado

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 may 2026, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 may 2026, 16:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

26 may 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

26 may 2026, 16:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Auto & Transport Roundup: Market Talk

26 may 2026, 16:16 UTC

Charlas de Mercado

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 may 2026, 16:01 UTC

Charlas de Mercado

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 may 2026, 15:21 UTC

Charlas de Mercado

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Comparación entre iguales

Cambio de precio

Simulations Plus Inc previsión

Precio Objetivo

By TipRanks

4.1% repunte

Estimación a 12 Meses

Media 16 USD  4.1%

Máximo 16 USD

Mínimo 16 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Simulations Plus Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

2

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

26 / 344 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat